Zoetis-Betrola deal sparks Australian competition concerns
( February 16, 2022, 22:36 GMT | Official Statement) -- MLex Summary: Zoetis Australia Research and Manufacturing, a subsidiary of Zoetis, will see its planned acquisition of Betrola, including its wholly owned subsidiary Jurox, face an extended review in Australia, after the country's regulator raised concerns with the planned merger. In a statement of issues released today, the Australian Competition & Consumer Commission said its preliminary view was that the proposed acquisition may substantially lessen competition in the supply of five companion-animal product areas, including pre-anaesthetics and sedatives, as well as injectable penicillin. For production-animal markets, the ACCC is concerned the deal may substantially lessen competition in four markets, including sheep parasiticides. The regulator has revised its timeline for the ongoing public review, with a new deadline set today for an announcement on April 28. A parallel review in New Zealand is due to conclude tomorrow.The Australian Competition & Consumer Commission's media release follows; the regulator's statement of issues is attached....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline